Open Access<p>Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome</p>
Author(s) -
David C. Metz,
Eric Liu,
Vijay N. Joish,
Lynn Huynh,
Todor Totev,
Mei Sheng Duh,
Kiernan Seth,
Susan Giacalone,
Pablo Lapuerta,
Michael A. Morse
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s276519
Subject(s) - medicine , carcinoid syndrome , tumor progression , progression free survival , neuroendocrine tumors , clinical trial , gastroenterology , oncology , cancer , overall survival
The TELEACE study showed reductions in tumor size in patients with neuroendocrine tumors, receiving telotristat ethyl in US clinical practice. Here, we report progression-free survival, time to tumor progression, changes in carcinoid syndrome symptoms, and indictors of overall health.